Latest Daily News

Latest News
June 4, 2017

In view of these findings, investigators in the IDEA collaboration reached a clinical consensus to recommend a risk-based approach to selecting adjuvant chemotherapy for stage III colon cancer. 

Read more

June 4, 2017

The BILCAP randomized study examined a cancer type for which “outcomes are poor—the 1- and 5-year survival rates are 22% and 9%, respectively,” said presenter Dr. John N. Primrose.

Read more
June 4, 2017

A planned interim analysis of the OPTIMAL˃60 trial found that a PET-based radiotherapy strategy to treat bulky disease is safe in elderly patients with diffuse large B-cell lymphoma.

Read more
June 4, 2017

In patients with upper tract urothelial carcinoma or who have early onset bladder cancer, screening for Lynch syndrome and germline testing is highly recommended.

Read more
June 4, 2017

Participants discussed 5- and 10-year follow-up data from two separate studies presented during the Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Oral Abstract Session.

Read more

June 4, 2017

Adding abiraterone to androgen-deprivation therapy increased overall survival among men with locally advanced or hormone-sensitive metastatic prostate cancer.

Read more

June 3, 2017

Presenters discussed current concepts regarding the treatment of early-stage disease, along with efforts to better enhance local control.

Read more

June 3, 2017

Three experts provide an update on the latest developments in the classification of ovarian cancer, current treatment approaches, and future directions.

Read more

June 3, 2017

Although patients have benefited from the expansion of options, questions have arisen about how to select optimal treatment, such as whether to recommend lymph node dissection or immunotherapy compared with targeted therapy.

Read more
June 3, 2017

Here are some bite-sized articles from Sunday's ASCO Daily News coverage.

Read more
June 3, 2017

Dr. James P. Allison and Dr. Suzanne L. Topalian highlighted the transformative nature of immune checkpoint inhibitors on cancer treatment and outlined a roadmap for future research.

Read more

June 3, 2017

Pembrolizumab is a potentially viable treatment for a subset of sarcomas, with promising activity in undifferentiated pleomorphic sarcoma and liposarcoma.

Read more
June 3, 2017

Aldoxorubicin prolonged progression-free survival in patients with liposarcoma and leiomyosarcoma (L-sarcoma) compared with standard treatments in a phase III study.

Read more

June 3, 2017

Median overall survival (OS) was 7.4 months longer among patients with platinum-sensitive, relapsed ovarian cancer who were given chemotherapy with cediranib followed by maintenance therapy with cediranib in the ICON6 trial.

Read more
June 3, 2017

A combined modality regimen did not increase recurrence-free survival in patients with optimally debulked stage III/IVA endometrial carcinoma.

Read more
June 3, 2017

Not only did lymphadenectomy yield no improvement in overall survival, but patients who underwent the procedure faced greater morbidity in terms of serious postoperative complications and greater early mortality following surgery.

Read more

June 3, 2017

Abemaciclib combined with the estrogen inhibitor fulvestrant may significantly reduce the risk of disease progression and increase the objective response rate in women with metastatic breast cancer, according to the results of the MONARCH 2 study.

Read more

June 3, 2017

TRK is uncommonly expressed in normal tissues and in most cancers, and TRK fusions are found in a diverse range of cancer types.

Read more
June 3, 2017

Two studies presented during the 2017 ASCO Annual Meeting provided additional evidence of the efficacy and safety of the CDK4/6 inhibitor ribociclib plus letrozole as a first-line treatment for ER-positive/HER2-negative advanced breast cancer. 

Read more

June 3, 2017

Dr. Jeffrey Weber discusses how lessons learned from the use of checkpoint inhibitors in melanoma can be applied to immunotherapy for other cancers.

Read more